Discover
ACRV
Acrivon Therapeutics, Inc.
1.73
2 x 1.29
2 x 2.22
bid
ask
-
0.05
2.81%
2 @ 04:00 AM
1.72 -0.01 (0.58%)
| Ytd | -28.22% | |
| 1y | 40.65% |
1.72
day range
1.81
1.20
52 week range
3.56
| Open | 1.77 | Prev Close | 1.78 | Low | 1.72 | High | 1.81 | Mkt Cap | 74.05M |
| Vol | 276.86K | Avg Vol | 571.04K | EPS | -2.00 | P/E | N/A | Forward P/E | -2.31 |
| Beta | N/A | Short Ratio | 15.38 | Inst. Own | 75.98% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 1.72 | 200-d Avg | 1.86 | 1yr Est | 21.11 |
| Income Statement | |||
| Operating Expenses | 19.90M | ||
| Research and Development Expense | 15.17M | ||
| Selling, General and Administrative Expense | 4.74M | ||
| Operating Income | -19.90M | ||
| Net Income | -19.04M | ||
| Net Income Common Stock | -19.04M | ||
| Net Income Common Stock (USD) | -19.04M | ||
| Consolidated Income | -19.04M | ||
| Earnings per Basic Share | -0.49 | ||
| Earnings per Basic Share (USD) | -0.49 | ||
| Earnings per Diluted Share | -0.49 | ||
| Earning Before Interest & Taxes (EBIT) | -19.04M | ||
| Earning Before Interest & Taxes (USD) | -19.04M | ||
| Weighted Average Shares | 38.72M | ||
| Weighted Average Shares Diluted | 38.72M | ||
| Balance Sheet | |||
| Cash and Equivalents | 34.26M | ||
| Cash and Equivalents (USD) | 34.26M | ||
| Investments | 63.67M | ||
| Investments Current | 63.67M | ||
| Current Assets | 99.22M | ||
| Property, Plant & Equipment Net | 6.91M | ||
| Total Assets | 107.83M | ||
| Debt Current | 1.15M | ||
| Total Debt | 2.42M | ||
| Current Liabilities | 11.05M | ||
| Debt Non-Current | 1.26M | ||
| Total Liabilities | 12.32M | ||
| Accumulated Retained Earnings (Deficit) | -293.92M | ||
| Accumulated Other Comprehensive Income | 4.00K | ||
| Shareholders Equity | 95.52M | ||
| Shareholders Equity (USD) | 95.52M | ||
| Assets Non-Current | 8.61M | ||
| Total Debt (USD) | 2.42M | ||
| Liabilities Non-Current | 1.26M | ||
| Trade and Non-Trade Payables | 1.16M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 656.00K | ||
| Net Cash Flow from Financing | -33.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -7.44M | ||
| Capital Expenditure | -14.00K | ||
| Net Cash Flow from Investing | 13.13M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 13.14M | ||
| Net Cash Flow from Operations | -20.54M | ||
| Share Based Compensation | 2.18M | ||